Compare STOK & DV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STOK | DV |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2019 | 2021 |
| Metric | STOK | DV |
|---|---|---|
| Price | $27.86 | $10.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 17 |
| Target Price | ★ $34.50 | $16.59 |
| AVG Volume (30 Days) | 812.5K | ★ 2.1M |
| Earning Date | 11-04-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.68 | 0.26 |
| Revenue | $205,632,000.00 | ★ $733,324,000.00 |
| Revenue This Year | $430.24 | $17.87 |
| Revenue Next Year | N/A | $10.40 |
| P/E Ratio | $41.92 | ★ $39.89 |
| Revenue Growth | ★ 1128.17 | 14.86 |
| 52 Week Low | $5.35 | $7.64 |
| 52 Week High | $38.69 | $23.11 |
| Indicator | STOK | DV |
|---|---|---|
| Relative Strength Index (RSI) | 40.11 | 38.31 |
| Support Level | $25.21 | $10.73 |
| Resistance Level | $31.70 | $11.12 |
| Average True Range (ATR) | 2.09 | 0.35 |
| MACD | -0.58 | -0.09 |
| Stochastic Oscillator | 27.86 | 17.54 |
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
DoubleVerify Holdings Inc is a digital media measurement and analytics software platform. Its solutions provide advertisers with unbiased data analytics that enable them to increase the effectiveness, quality, and return on their digital advertising investments. Its DV Authentic Ad, a proprietary metric of digital media quality, measures whether a digital ad was delivered in a brand-suitable environment, fully viewable, by a real person, and in the intended geography. The company's software interface, DV Pinnacle, delivers these metrics to customers in real time, allowing them to access critical performance data on their digital transactions. Geographically, the company operates in the United States and also has a presence in Germany, Singapore, France, Canada, Japan, and other countries.